CRUSHing Lab Fraud: Three Myths that Derail Real Reform – Image for illustrative purposes only (Image credits: Unsplash)
The Centers for Medicare & Medicaid Services issued a Request for Information in February as part of its Comprehensive Regulations to Uncover Suspicious Healthcare initiative, known as CRUSH. This move spotlighted persistent issues of fraud, waste, and abuse in laboratory testing, particularly within genetic and molecular diagnostics. As the industry prepares its response, familiar defenses are likely to surface, potentially undermining efforts to protect Medicare spending and patient care. Policymakers must scrutinize these arguments to drive meaningful change that safeguards taxpayer dollars and healthcare quality.
Fraud as Isolated Incidents? The Evidence Says Otherwise
Laboratory representatives often portray fraud, waste, and abuse as the work of a small number of rogue operators. They highlight high-profile enforcement cases as proof that the system largely polices itself. However, Medicare billing patterns reveal a broader problem rooted in industry practices.
Practices like code stacking exemplify this trend. Laboratories frequently billed multiple codes for hereditary cancer panels instead of a single panel code, leading to charges that varied widely from $679 to $8,589 for similar tests. Whistleblower reports and Justice Department settlements further document recurring issues, including high-volume genetic panels ordered without strong clinical need and permissive billing for molecular pathology tests. Opacity in laboratory-developed tests compounds the challenge, as tests with varying accuracy share similar names, enabling questionable ones to secure reimbursement alongside validated options.
Precision Medicine’s Promise Versus Soaring Medicare Costs
Industry advocates frequently invoke the era of precision medicine to defend escalating expenses. They argue that genetic testing drives better outcomes, making it a sound investment for Medicare despite its rapid growth. Recent 2024 data underscores the scale: genetic tests comprised 43% of Medicare’s outpatient laboratory spending, or $3.6 billion, even though they represented just 5% of tests performed.
While certain genetic tests have shown clear benefits in diagnosis and treatment, many others lack robust evidence of clinical utility. Tests marketed similarly to proven ones often differ in methodology and performance, yet they benefit from the same billing codes and branding. This creates an illusion of widespread value that does not hold up under scrutiny. For Medicare beneficiaries, the result is higher costs without guaranteed improvements in health.
Without test-specific proof of impact, these expenditures strain the program that millions of older Americans rely on. The distinction between aspirational potential and demonstrated results remains crucial for justifying public funds. Policymakers evaluating coverage must demand evidence that ties each test to tangible patient benefits, rather than accepting category-wide assumptions.
Oversight as a Threat to Innovation? A Flawed Assumption
Labs warn that tighter rules on billing and patient recruitment would hinder diagnostic breakthroughs and delay life-saving tools. This view assumes the current surge in testing volume equates to progress. In reality, unchecked growth often prioritizes quantity over quality.
Efforts to test broadly, even beyond appropriate patient groups, can dilute a test’s true utility and introduce risks like false positives. Absent billing standards, the market favors unproven alternatives that undercut high-quality options. Stricter oversight would instead channel resources toward validated advances, ensuring Medicare supports tests that genuinely aid patients.
Steps Toward Transparency and Accountability
Addressing these issues requires shifting from reactive enforcement to systemic fixes. CMS could mandate distinct billing names for tests differing in design or performance, reducing opportunities for misrepresentation. Reimbursement decisions should hinge on individual test evidence, not broad inferences.
These changes would curb waste without stifling genuine innovation. For everyday Americans, the stakes involve more than policy details – they mean preserving Medicare’s solvency amid rising healthcare bills. The CRUSH initiative offers a chance to prioritize proven value, fostering a laboratory sector that delivers on precision medicine’s potential while protecting public resources.
